Evidence map›Paper›PMID 30370061›Full record

ArticleJournal of clinical and translational science2018

Right now, in the right way: U. S. Food and Drug Administration's expanded access program and patient rights.

M E Blair Holbein, Kevin J Weatherwax, Misty Gravelin, Raymond Hutchinson, George A Mashour

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and translational science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

M E Blair HolbeinDepartment of Clinical Sciences, Center for Translational Medicine, UT Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0003-1368-4571
Kevin J WeatherwaxMichigan Institute for Clinical and Health Research (MICHR), University of Michigan, Ann Arbor, MI, USA.
Misty GravelinMichigan Institute for Clinical and Health Research (MICHR), University of Michigan, Ann Arbor, MI, USA.
Raymond HutchinsonMichigan Medicine, University of Michigan Medical School, University of Michigan, Ann Arbor, MI, USA.
George A MashourMichigan Institute for Clinical and Health Research (MICHR), Office of Research, University of Michigan, Ann Arbor, MI, USA.

Funding

Michigan Institute for Clinical and Health Research (MICHR)UL1TR002240 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUMENG, JULIE C, MASHOUR, GEORGE ALEXANDER · 2017 to 2022
$54.9M
UT Southwestern Center for Translational Medicine (UL1/KL2/TL1)UL1TR001105 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2013 to 2017
$24.5M
TEAMSS – Transforming Expanded Access to Maximize Support & StudyU01TR002488 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER, WEATHERWAX, KEVIN J · 2018 to 2022
$4.8M
NCATS NIH HHS U01 TR002488NCATS NIH HHS UL1 TR001105NCATS NIH HHS UL1 TR002240
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

compassionate useethicsInvestigational drugslegislationpatient rightsUnited States Food and Drug Administration

Identifiers

PMID30370061
PMCPMC6202008

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.